Web-applicationWEBAPPACNCT04554927
Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer
A study testing WEB-Application and Standard accompaniment in people with Web-application and Breast Cancer, run by Centre Francois Baclesse at 1 site in France.
Trial summary
The investigators hypothesize that the implementation of a Web-application in patients initiating adjuvant hormone therapy for breast cancer brings a benefit on treatment adherence and quality of life. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Web-application, Breast Cancer, Hormono Therapy
- What is being tested?
- WEB-Application and Standard accompaniment
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 438 participants
- Where
- 1 siteFrance
- Study dates
- 3 Sep 2020to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient > 18 years old
- Breast cancer patient candidate for adjuvant hormone therapy
- Mastery of the French language
- Patient with a cell phone and an Internet connection
- Patient able to use a computer, smartphone, or tablet.
- Patient affiliated to a social security system
- Signing of informed consent prior to any specific study-related procedure
Who cannot join
- Patient who has previously received hormone therapy for cancer.
- Patient not trained in the use of the application
- Any associated medical or psychiatric condition that might compromise the patient's ability to participate in the study
- Patients with locoregional or metastatic recurrence
- Other history of cancer.
- Patient deprived of liberty, under guardianship or curatorship
- Simultaneous participation in a therapeutic clinical trial or other clinical study involving a connected tool
- Patient unable to undergo trial follow-up for geographical, social or psychopathological reasons
Trial locations and contacts
1 site in 1 country.
About this study
The investigators hypothesize that the implementation of a Web-application in patients initiating adjuvant hormone therapy for breast cancer brings a benefit on treatment adherence and quality of life.
- Conditions
- Web-application, Breast Cancer, Hormono Therapy
- Being tested
- WEB-Application, Standard accompaniment
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
WEB-ApplicationOther
The patients of the Web-application arm will be trained on the devices and the application will be installed either on their smartphone or on another support (computer, tablet).
Standard accompanimentOther
Personalized schedule of medical follow-up given to the patient
| Study group | Role | What they receive |
|---|---|---|
| WEB-application | Experimental | Not described Receives: Other: WEB-Application |
| Standard accompaniment | Active comparator | Not described Receives: Other: Standard accompaniment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Observance of hormontherapy
Evaluate the benefit of a web-based application on hormone therapy compliance (Morisky questionnary; answer Yes or No; 8 questions)
Measured: 18 months
Secondary outcomes (2)
Quality of life with self questionnaires
Quality of life scores according (EORTC QLQ-C30 self-questionnaires ; minimum not at all to maximum Lot; 30 questions)
Measured: 18 months
Quality of life with self questionnaires
uality of life scores according (EORTC QLQ-BR23 self-questionnaires ; minimum not at all to maximum Lot; 23 questions)
Measured: 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2020
- Study start3 Sep 2020
- Primary completion11 Oct 2024
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Web-applicationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 438 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Francois Baclesse
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04554927
- Sponsor's protocol ID
- WEBAPPAC
- Acronym
- WEBAPPAC
- Status last verified
- May 2026
- First submitted
- 14 Sep 2020
- Last updated
- 18 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Gernier F, Grellard JM, Dupont C, Castel H, Fernette M, Lahaye F, Charles RM, Leroux T, Ory C, Faveyrial A, Morel A, Emile G, Levy C, Segura C, Allouache D, Johnson A, Geffrelot J, Gunzer K, Lelaidier A, Girault G, Dubot-Poitelon C, San C, Lequesne J, Clarisse B. Impact of web application support versus standard management on adherence with adjuvant hormone therapy in patients treated for breast cancer: the WEBAPPAC study. BMC Cancer. 2023 Aug 9;23(1):736. doi: 10.1186/s12885-023-11242-1.
PubMed 37559004
Study at a glance
From the registry record, last updated by the sponsor on 18 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer
- ClinicalTrials.gov ID
- NCT04554927
- Acronym / sponsor ID
- WEBAPPAC / WEBAPPAC
- Conditions
- Web-application, Breast Cancer, Hormono Therapy
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 438 participants (estimated)
- Lead sponsor
- Centre Francois BaclesseUniversity, hospital or other
- Study start
- 3 Sep 2020 (actual)
- Primary completion
- 11 Oct 2024 (actual)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 18 Sep 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators hypothesize that the implementation of a Web-application in patients initiating adjuvant hormone therapy for breast cancer brings a benefit on treatment adherence and quality of life.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| WEB-application | Experimental | Other: WEB-Application |
| Standard accompaniment | Active comparator | Other: Standard accompaniment |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Patient > 18 years old
- Breast cancer patient candidate for adjuvant hormone therapy
- Mastery of the French language
- Patient with a cell phone and an Internet connection
- Patient able to use a computer, smartphone, or tablet.
Key exclusion criteria (8 listed)
- Patient who has previously received hormone therapy for cancer.
- Patient not trained in the use of the application
- Any associated medical or psychiatric condition that might compromise the patient's ability to participate in the study
- Patients with locoregional or metastatic recurrence
- Other history of cancer.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| WEB-ApplicationThe patients of the Web-application arm will be trained on the devices and the application will be installed either on their smartphone or on another support (computer, tablet). | Other | WEB-application |
| Standard accompanimentPersonalized schedule of medical follow-up given to the patient | Other | Standard accompaniment |
Primary outcome
Observance of hormontherapy
Time frame: 18 months
Evaluate the benefit of a web-based application on hormone therapy compliance (Morisky questionnary; answer Yes or No; 8 questions)
2 secondary outcomes
Quality of life with self questionnaires
Time frame: 18 months
Quality of life with self questionnaires
Time frame: 18 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 May 2026.
- Derived from this study: PubMed 37559004Gernier F, Grellard JM, Dupont C, Castel H, Fernette M, Lahaye F, Charles RM, Leroux T, Ory C, Faveyrial A, Morel A, Emile G, Levy C, Segura C, Allouache D, Johnson A, Geffrelot J, Gunzer K, Lelaidier A, Girault G, Dubot-Poitelon C, San C, Lequesne J, Clarisse B. Impact of web application support versus standard management on adherence with adjuvant hormone therapy in patients treated for breast cancer: the WEBAPPAC study. BMC Cancer. 2023 Aug 9;23(1):736. doi: 10.1186/s12885-023-11242-1.
- Individual participant dataSharing planned: Undecided
Related trials for Web-application
Recruiting
Confident Moves Intervention Efficacy Trial: Obesity Care Settings
Obesity, Overweight
Not yet recruiting
Effect of a Web-based Application With Integrated AI Chat for Cardiovascular Risk Support
AI Chatbot, Cardiovascular (CV) Risk
Not yet recruiting
Developing and Validating Health Education Module for Prostate Cancer Prevention Behavior in Iraqi Male University Staff
Prostate Cancer, Health Knowledge, Attitudes, Practice
Active, not recruiting
IAMABLE: Implementation and Evaluation of an App for Evidence-Based Self-Management Rehabilitation Strategies
Neurological Conditions, Musculoskeletal Diseases or Conditions
Enrolling by invitation
Exploratory Trial of a Pediatric Web-Based Care Planning Guide
Developmental Disabilities, Developmental Delay
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing WEB-Application and Standard accompaniment in people with Web-application and Breast Cancer, run by Centre Francois Baclesse at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 18 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Observance of hormontherapy (time frame: 18 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04554927, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2026.